Paxlovid
Market Access/ News/ News/ News/ Patients
FDA backs pharmacist prescribing of Paxlovid for COVID
Phil Taylor
antiviral, coronavirus, COVID-19, fda, patients, Paxlovid, Pfizer, pharmacist, prescribing
0 Comment
News/ News/ Sales and Marketing
Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent
Phil Taylor
antiviral, coronavirus, COVID-19, Enanta Pharmaceuticals, patent litigation, Paxlovid, Pfizer
0 Comment
Market Access/ Views & Analysis/ Views and analysis
Six months after authorization, what do we know about Paxlovid?
mike.hammerton@pharmaphorum.com
COVID-19, fda, Paxlovid, Pfizer
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Pfizer makes non-profit pledge for low-income nations
Phil Taylor
Comirnaty, developing world, market access, Paxlovid, Pfizer, pricing
0 Comment
News/ News/ Sales and Marketing
Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year
Phil Taylor
biosimilars, Comirnaty, Eliquis, Financial, Paxlovid, Pfizer, Sales and Marketing, Vyndaqel
0 Comment
Update: Pfizer pips Merck to first oral COVID antiviral okay in US
Phil Taylor
antiviral, coronavirus, COVID-19, fda, Merck & Co, molnupiravir, Paxlovid, Pfizer
0 Comment
As Omicron cases rise, EMA backs early use of Pfizer’s Paxlovid
Phil Taylor
antiviral, coronavirus, COVID-19, Merck & Co, molnupiravir, Paxlovid, Pfizer
0 Comment
Truepill preps launch of virtual COVID-19 service for oral antivirals
Phil Taylor
antiviral, COVID-19, digital, digital health, Merck & Co, molnupiravir, Paxlovid, Pfizer, telehealth, Truepill
0 Comment